1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
ODI Pharma AB

ODI Pharma AB

ODI.ST
ODI Pharma ABSE flagStockholm Stock Exchange
2.26
SEK
+0.06
- -
41.43MMarket Cap
ODI Pharma AB
ODI.ST
(Stockholm Stock Exchange)

Recent

price

2.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
0.02
0.01
1.46
0.17
1.62
Revenue per Share
-0.48
- -
-0.36
-0.26
-0.48
-0.45
-0.04
-0.32
-0.02
Basic EPS, GAAP
-0.44
- -
-0.35
-0.4
-0.49
-0.33
-0.25
-0.18
0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
- -
0.04
0.04
0.04
0.04
0.04
0.04
0.04
Book Value per Share
0.53
- -
1.45
1.06
0.61
0.17
0.13
0.02
0.1
Tangible Book Value per Share
8
- -
14
15
15
15
15
19
18
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
22
3
30
Sales/Revenue/Turnover
- -
- -
- -
- -
-2,302.98
-4,884.2
1.92
-173.94
1.3
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-4
- -
-5
-4
-7
-7
-1
-6
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-2,313.25
-4,948.58
-2.55
-189.33
-0.94
Profit Margin (%)
4
4
20
16
9
3
2
-1
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
4
4
20
16
9
3
2
- -
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
165.08
Return on Capital (%)
- -
- -
-223.66
-654.02
-1,189.07
-1,133.56
-93.31
-884.24
-40.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
21
77
67

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
7
10
11
Cash, Cash Equivalents & STI
3
5
4
Accounts Receivable, Net
3
4
5
Inventories
- -
- -
- -
Total Current Liabilities
7
8
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-47.04%
-78.78%
Free Cash Flow
- -
-4.14%
-13.55%
Net Income, GAAP
- -
182.02%
944.49%
Sales/Revenue/Turnover
- -
- -
-85.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
- -
14
8
22
2025
- -
- -
3
- -
3
2026
6
11
13
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
0.06
0.09
-0.08
-0.04
2025
-0.1
-0.17
-0.02
-0.09
-0.32
2026
- -
0.07
0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Ionic Brands Corp. (IONC.CN)
FDC Limited (FDC.NS)
Cipher Pharmaceuticals Inc. (CPH.TO)
Acorda Therapeutics, Inc. (ACORQ)
Pure Extracts Technologies Corp. (PRXTF)
Avant Brands Inc. (AVNT.TO)
Business
ODI Pharma AB (publ), a Swedish pharmaceutical company founded in 2018 and headquartered at Oestermalmstorg 1 in Stockholm, specializes in the production and distribution of medical cannabis products and cosmetics across Europe, primarily targeting Eastern European medicinal markets through subsidiaries such as ODI Pharma Polska Sp. z o.o. and partnerships with wholesale distributors serving over 14,000 pharmacies, specialty clinics, and hospitals. The company offers pharmaceutical-grade dried cannabis flowers featuring varying THC and CBD levels for treating conditions including multiple sclerosis, chronic pain, and chemotherapy side effects; cannabis oils, capsules, tablets, and oromucosal sprays; and cosmetics under the Kandol brand, sourcing raw materials from global leaders like Tilray Brands Inc. to ensure quality and regulatory compliance without in-house cultivation. Recent developments include an exclusive supply collaboration with Synoptis Pharma Sp. z o.o., part of Poland's Neuca Group, positioning ODI as the primary medicinal cannabis provider in Poland and 22 other Eastern and Southeastern European countries following regulatory approval and a near-doubling of Poland's 2025 import quota; a January 2025 CEO appointment of Jan-Mark Edewaard; sale of the Kandol skincare brand for SEK 3.2 million; a rights issue raising approximately SEK 2.2 million net; and loan financing of EUR 350,000 to support expansion and financial strengthening.